KINASE INHIBITORS

This review article provides an overview of the main adverse events, risk assessment and risk mitigation strategies, early diagnosis, medical and complementary strategies for prevention and management, and long‐term follow‐up strategies for patients at risk of experiencing cancer therapy‐related cardiotoxicities

This position statement reviews the use of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging, and computed tomography in the management of cancer patients based on current evidence for the value of modern cardiovascular imaging in the cardio‐oncology field, and discusses future directions and ongoing cardiovascular imaging research.

This position statement presents evidence‐based risk stratification tools for oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities.

The most recent update to the NCCN Survivorship guidelines has added a new algorithm for cardiovascular disease risk assessment among cancer survivors, which includes the ABCDEs to Promote Cardiovascular Wellness (SCVD-1 and SCVD-1).

This review article explores the links between cancer, cancer treatment, and cardiovascular risk, including mechanisms associated with cardiotoxicity, screening and surveillance for patients undergoing cancer treatment, and effective preventative and management strategies used to reduce the incidence of cardiotoxicities in patients receiving chemotherapeutics or radiation.

This curated resource from the American College of Cardiology offers links to cardio-oncology news and JACC journal articles, education and meeting opportunities, and tools and practice support for clinicians.

Through this webpage, the International Cardio-Oncology Society provides myriad resources to help both clinicians and patients stay aware and informed about the latest in cardio-oncology.

Discover the myocardial biology behind cardiotoxicity associated with kinase inhibitor therapies through this presentation from the 2019 FDA conference, “Cardiomyocytes for Mechanistic Cardiovascular Safety Liabilities."

Take a deep dive into the clinical mitigation and management of osimertinib-induced heart failure in a 67-year old patient with metastatic EGFR-mutant lung adenocarcinoma and a history of hypertension, hypothyroidism, and pulmonary embolism in this Clinical Case Challenge.

This Viewpoint article highlights the importance of reconsidering certain clinical visits, including imaging tests, for patients with cancer and/or cardiovascular disease during the ongoing COVID-19 pandemic. The authors also provide general guidance, based on available evidence, regarding the role of routine cardiac surveillance as the novel coronavirus continues to be a threat.

Developed by an American Society of Clinical Oncology expert panel and based on a systematic review of literature, these guidelines equip health care providers to discuss potential cardiac dysfunction with patients at high risk and initiate appropriate prevention and screening measures prior to beginning therapy.

Walk through the case of a 61-year-old patient with chronic myeloid leukemia and no cardiovascular history experiencing cardiac side effects associated with nilotinib treatment, including management and clinical perspective in this Clinical Case Challenge.

These recommendations offer a critical summary of adverse events that emerge during CML treatment, as well as guidelines for management and prevention, in an effort to improve TKI compliance and improve outcomes.

Stay up to date about emerging research on the cardiotoxicities seen with many types of cancer therapy. Learn about why these cardiac effects occur, and how to best monitor for and manage them in your patients. 

Learn about the development and implementation of a cardio-oncology program in a suburban community cardiology practice, created to provide service in this area to breast cancer patients at risk for cardiotoxicity, including the use of the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework to guide the project and enhance the translation of research into practice through planning and execution.

Take a deep dive into the clinical mitigation and management of osimertinib-induced heart failure in a 67-year old patient with metastatic EGFR-mutant lung adenocarcinoma and a history of hypertension, hypothyroidism, and pulmonary embolism in this Clinical Case Challenge.

This review explores current data on risk factors, diagnoses, and treatment options that impact cardio-oncologic patients with COVID-19, in addition to offering strategies for the treatment and management of this population.

The patient section of the Canadian Cardiac Oncology Network’s site offers patients access to information about cardiac oncology, including educational resources, clinical trials, and research articles, in addition to a frequently asked questions list and Canadian-specific clinic search.

This resource provides a click-through and searchable listing of cancer drugs, their drug class and cancer indications, and their associated cardio-toxicities, to help clinicians stay informed when treating their patients.

Explore the existing literature relating to chemotherapy- and radiotherapy-induced cardiotoxicity in this review. Also learn about the imaging modalities used to identify cardiotoxicity, as well as prevention and management therapies.

This expert analysis from the American College of Cardiology takes a deep dive into the risk of atrial fibrillation associated with the Bruton kinase inhibitor ibrutinib and a proposed algorithm for management of this toxicity.

Educate yourself and your team members about the growing list of BTK inhibitors, where they fit in the treatment landscape, and how to successfully manage patients receiving these agents. 

Find guidance on managing various cardiotoxicities associated with kinase inhibitors approved for the treatment for B-cell lymphomas.

Find guidance on managing various cardiotoxicities associated with kinase inhibitors approved for the treatment for CLL/SLL.

Find guidance on managing various cardiotoxicities associated with kinase inhibitors approved for the treatment for CML